Monitor for actual sales near the January 12, 2026 date; since this is under a pre-established 10b5-1 plan, it carries less negative signal than an ad-hoc sale, but traders should still watch for execution as it may coincide with other catalysts.
TSHA drugs
TSHA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 13 $4.42entry
- T+1 · 7mo ago +6.56%α +5.35% · $4.71
- T+5 · 7mo ago +46.15%α +42.86% · $6.46
- T+20 · 6mo ago +54.30%α +46.57% · $6.82
- T+60 · 4mo ago +46.83%α +37.91% · $6.49
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Nagendran Sukumar, an officer of Taysha Gene Therapies, filed a Form 144 to notify intent to sell up to 200,000 shares of common stock, valued at approximately $942,740, under a 10b5-1 selling plan adopted on June 11, 2025. The sale is scheduled for January 12, 2026.
Key Facts
- Reporting person: Nagendran Sukumar, officer of TSHA
- Number of shares proposed for sale: 200,000
- Approximate value of shares: $942,740
- Sale date: January 12, 2026
- Sales to be executed under a 10b5-1 plan adopted on June 11, 2025
- Shares are common stock issued from prior RSU and stock option grants
Financial Impact
Approximately $942,740 in potential near-term selling pressure from an insider, representing a small fraction of TSHA's $1.3B market cap.
Risk Factors
- Potential perception of insider selling ahead of earnings or clinical trial readouts
- Execution of sale could contribute to short-term downward price pressure if market conditions are weak
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001974158-26-000040 |
| Document: 0001974158-26-000040-index.html | 0001974158-26-000040 |
| Document: 0001974158-26-000040.txt | 0001974158-26-000040 |
Track record
14 reports on TSHA
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +20.50% at T+60 after the Jun 25, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $4.06 Now $4.06 −0.00% settles Feb 16
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $4.21 Now $4.06 −3.56% settles Feb 10
- Aug 11, 202613w ago Press Release Neutral 5/10 Entry $6.41 to $4.09 Now $4.06 −36.61% ▼ −36.14% −31.03% vs SPY
- Jun 25, 202620w ago 8-K Mixed 5/10 Entry $6.34 to $5.04 Now $4.06 −35.96% ▼ −20.50% −26.61% vs SPY
- Jun 25, 202620w ago 424B5 Bearish 6/10 Entry $6.34 to $5.04 Now $4.06 +35.96% ▲ +20.50% +26.61% vs SPY
- Jun 24, 202620w ago Press Release Bearish 7/10 Entry $6.21 to $5.02 Now $4.06 +34.62% ▲ +19.16% +22.89% vs SPY
- Jun 5, 202623w ago Press Release Neutral 2/10 Entry $5.50 to $5.69 Now $4.06 −26.18% ▲ +3.45% −0.55% vs SPY
- May 6, 202627w ago 8-K Neutral 5/10 No price data
- May 6, 202627w ago Press Release Mixed 7/10 Entry $6.98 to $5.86 Now $4.06 −41.83% ▼ −16.05% −18.11% vs SPY
- Apr 29, 202628w ago Press Release Neutral 1/10 Entry $6.27 to $5.52 Now $4.06 −35.25% ▼ −11.96% −16.07% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers